Is there an easy way to see if my diabetes is getting worse, without daily pricks?

For most people living with type 2 diabetes, the question is rarely whether they are managing the disease today. It is whether the disease is quietly getting worse in the background, between the moments they actually pay attention to it. The fingerstick was supposed to answer that question, but it answers only one number at one moment, and it hurts enough that many people stop doing it. Diabetes remote monitoring has become the practical response to this gap, giving chronic care management teams a way to watch trends without asking patients to draw blood several times a day. For the organizations responsible for these patients, the appeal is straightforward: monitoring that people will actually keep doing produces data, and data nobody collects helps no one.

A 2023 cross-sectional study by Lin, Chen, and Fan found that only 26.2% of type 2 diabetes and pre-diabetes patients in community settings met self-monitoring of blood glucose standards, with needle pain and inconvenience among the leading reasons people stopped.

What diabetes remote monitoring actually measures

The instinct is to assume that watching diabetes means watching glucose. That is part of it, but it is not the whole picture, and for the patient asking whether their disease is worsening, glucose is not the only signal worth tracking. Diabetes remote monitoring covers a range of approaches, from continuous glucose sensors that report interstitial readings every few minutes, to remote patient monitoring programs that collect connected glucometer data, to contactless check-ins that capture vital signs and physiological trends without any wearable or lancet at all.

Each method answers a slightly different question. A glucose sensor tells you where blood sugar sits right now and how often it spends time in range. A contactless daily check-in tells you whether the body's broader pattern, resting heart rate, heart rate variability, respiratory rate, is drifting in a direction that often accompanies worsening metabolic control or a developing complication. Neither replaces a clinical A1c test, but together they shorten the time between a problem starting and someone noticing it.

The reason this matters for chronic care management companies is adherence. A monitoring method that produces excellent data for two weeks and then gets abandoned is worse than a modest method people sustain for a year. The evidence on fingerstick adherence is sobering, and it explains why so much of the field has moved toward lower-burden options.

Monitoring method	Daily burden on patient	What it captures	Typical sustained adherence
Fingerstick self-monitoring	High (painful, repeated)	Single glucose value per test	Often 26 to 50% per published studies
Continuous glucose sensor	Moderate (applied device, replacement)	Glucose trend, time in range	Higher than fingerstick, varies by system
Connected glucometer with RPM	Moderate to high	Glucose values, transmitted	Around 48.7% in Medicaid cohort study
Contactless daily vitals check-in	Low (no device worn, no blood)	Heart rate, HRV, respiratory trends	Designed for daily routine, minimal friction

Why the burden question drives outcomes

The pain point is not abstract. Patients describe self-monitoring of blood glucose as painful, time consuming, frustrating, and at times demoralizing. When a behavior carries that emotional weight, people do less of it, and the gaps in the record are exactly where deterioration hides.

A few patterns emerge consistently across the research:

• Pain at the needle site is one of the strongest predictors of whether someone keeps testing, according to Lin, Chen, and Fan (2023).
• Adherence falls further when patients do not clearly understand their target range or why a given testing frequency matters.
• Remote patient monitoring improves engagement compared with unsupported self-testing, but even RPM programs see roughly half of patients hitting the every-other-day testing threshold.
• Lower-friction methods reduce the dropout that turns a monitoring program into a list of names with no recent data.

For a value-based care organization, that last point is the financial one. Reimbursement and shared-savings models assume a steady stream of patient data. Monitoring people will not sustain undermines the entire economic case.

Industry applications for chronic care teams

Catching the slow slide before the crisis

The clinical value of any monitoring program is its ability to flag a worsening trajectory while there is still time to intervene with a medication adjustment or a coaching call. Diabetes rarely worsens overnight. It drifts. A patient whose control is slipping may show subtle physiological changes well before their next scheduled A1c. Daily contactless check-ins let care managers watch for that drift across a whole panel without waiting for the quarterly lab.

Reaching patients who refuse devices

Device fatigue is real, and it is not limited to diabetes. Many patients with multiple chronic conditions are already asked to wear or carry several pieces of equipment. A contactless approach that uses a phone or tablet camera for a brief daily check-in sidesteps the refusal entirely. For chronic care management companies trying to enroll and retain patients who have already opted out of wearables, this is often the difference between a populated dashboard and an empty one.

Supporting non-insulin type 2 populations

A large share of type 2 patients are not on intensive insulin and may not need minute-by-minute glucose data. For this group, the more useful signal is whether their overall pattern is stable or trending poorly. A randomized trial of continuous glucose monitoring paired with remote telemonitoring and virtual educator visits showed meaningful A1c improvement in non-insulin type 2 adults, which suggests the combination of any objective monitoring plus human follow-up is what moves outcomes, not the lancet specifically.

Current research and evidence

The published record points in a consistent direction. A real-world retrospective cohort study of Medicaid patients with diabetes reported that 48.7% were adherent to blood glucose testing, defined as testing on at least 80% of days, even within a structured remote patient monitoring program. That number is higher than unsupported self-monitoring but still leaves half the population under-monitored.

On the glucose side, work synthesized in the American Diabetes Association Standards of Care in Diabetes 2024 documents that continuous glucose monitoring is associated with A1c reductions, with one analysis citing an overall 0.7% improvement after initiation and a 0.9% reduction specifically among type 2 patients not on insulin. A separate systematic review and meta-analysis on type 2 diabetes reported a pooled HbA1c effect of roughly -0.37%. The signal is real but modest, and it depends heavily on patients continuing to use the system.

The adherence research from Lin, Chen, and Fan (2023), along with a 2024 Saudi Arabian study finding only 14.3% of patients in the high-adherence category for self-monitoring, reinforces the same conclusion: the limiting factor in diabetes monitoring is rarely the technology's precision. It is whether the patient sustains the behavior. That reframes the whole problem for chronic care teams from "how accurate is each reading" to "how many readings will we actually get over twelve months."

The future of diabetes remote monitoring

The direction of travel is toward methods that ask less of the patient while still producing a usable trend. Three shifts are worth watching.

• Multimodal monitoring, where contactless vitals provide daily continuity and periodic glucose or A1c data anchors the clinical picture, rather than relying on a single stream.
• Earlier detection of complications, including autonomic changes that show up in heart rate variability before they appear in routine labs.
• Integration with care management workflows so that a worsening trend triggers a human contact, not just another alert in a queue.

The patient asking whether there is an easier way to see if their diabetes is getting worse is really asking for monitoring that fits into a normal life. The organizations serving that patient are asking a parallel question: how do we collect enough sustained data to manage risk and meet quality targets without losing people to device fatigue. Both questions point to the same answer, which is lower-burden, daily, contactless monitoring that complements rather than replaces clinical testing.

Frequently asked questions

Can diabetes remote monitoring replace A1c testing? No. A1c remains the standard clinical measure of long-term glucose control. Remote monitoring fills the long gaps between A1c tests, helping teams notice a worsening trend earlier and act on it sooner.

How can a patient track diabetes without daily fingersticks? Options include continuous glucose sensors and, for many patients, contactless daily check-ins that capture physiological trends like resting heart rate and heart rate variability without any blood draw or worn device. These work best alongside periodic clinical testing.

Why does monitoring burden matter so much for chronic care programs? Published studies show fingerstick adherence often falls between 26 and 50%, largely due to pain and inconvenience. Programs that reduce that burden collect more consistent data, which is essential for risk management and value-based care reporting.

What signals suggest diabetes is getting worse between visits? Rising glucose patterns and reduced time in range are direct signals. Indirect signals such as changes in heart rate variability can also accompany worsening control or developing complications, which is why broader vitals monitoring adds value.

Circadify is building toward this space with daily contactless check-ins designed for diabetes, heart failure, and COPD populations that struggle with device fatigue. Chronic care management and value-based care teams evaluating lower-burden ways to keep diabetes patients monitored between visits can review program details at circadify.com/solutions/chronic-care-management.